New drug EDG-7500 put to the test in liver health study
NCT ID NCT07324616
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This early-stage study is testing a single dose of an experimental drug called EDG-7500 in 32 adults. Some have mild or moderate liver problems, while others have normal liver function. Researchers want to see how the drug moves through the body and if it is safe in people with different levels of liver function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EDG-7500
- What this could lead to
- If successful, this study could help determine safe dosing of EDG-7500 for people with liver problems.
- What could go wrong
- This is a very early Phase 1 study with only 32 participants. It is designed to measure drug levels, not to treat any disease, so it may not lead to a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (HI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
The University of Miami Division of Clinical Pharmacology
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.